<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01787162</url>
  </required_header>
  <id_info>
    <org_study_id>24-393 ex 11/12</org_study_id>
    <nct_id>NCT01787162</nct_id>
  </id_info>
  <brief_title>Screening for Pulmonary Vascular Changes in Patients With Chronic Myeloproliferative Diseases</brief_title>
  <official_title>Screening for Pulmonary Vascular Changes in Patients With Chronic Myeloproliferative Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Goal of the study is to assess the frequency of pulmonary hypertension in patients with&#xD;
      chronic myeloproliferative diseases. In each patient an echocardiography at rest will be&#xD;
      performed. In patients without musculoskeletal disease an exercise test (spiroergometry) will&#xD;
      be performed. Patients with elevated SPAP at rest or with reduced exercise capacity (peak VO2&#xD;
      &lt; 65%) a right heart catheterization (RHC) will be recommended. Also patients with advanced&#xD;
      NYHA functional class (III or IV) or with typical PH findings in electrocardiogram will be&#xD;
      advised to undergo a RHC. Additionally for the evaluation of exercise capacity a 6 MWD will&#xD;
      be performed.&#xD;
&#xD;
      This work- up of patients allows clinical and hemodynamic evaluation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous small studies and clinical cases have suggested a possible association between&#xD;
      pulmonary hypertension (PH) and chronic myeloproliferative disorders (CMPD). MPD may cause PH&#xD;
      through different mechanisms as: high cardiac output, asplenia, direct obstruction of&#xD;
      pulmonary arteries by megakaryocytes, chronic thromboembolic endothelial pulmonary&#xD;
      hypertension (CTEPH), porto-pulmonary hypertension (POPH). However, the exact prevalence of&#xD;
      PH in this group of disorders is not known.&#xD;
&#xD;
      This study is designed to identify the pulmonary vascular changes and describe the prevalence&#xD;
      of pulmonary hypertension (defined in this study as mean pulmonary arterial hypertension&#xD;
      (mPAP) ≥25mmHg as assessed by right-heart catheterization (RHC) or systolic pulmonary&#xD;
      arterial pressure (sPAP) ≥37mmHg (2.9 m/s) assessed by echocardiography.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>pulmonary arterial pressure</measure>
    <time_frame>at baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of pulmonary arterial pressure</measure>
    <time_frame>between baseline and after 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">43</enrollment>
  <condition>Myeloproliferative Disorders</condition>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>myeloproliferative disorders</arm_group_label>
    <description>Echocardiography, spiroergometry, cardiac catheterization</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Echocardiography, spiroergometry, cardiac catheterization</intervention_name>
    <description>patients with CMPD will undergo echocardiography, spiroergometry, and right heart catheterization, if indicated</description>
    <arm_group_label>myeloproliferative disorders</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples with DNA will be retained for later examinations at the Biobank, in case that the&#xD;
      patient agrees (extra patient information).&#xD;
&#xD;
      The blood samples are taken only during routine tests.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with myeloproliferative disorders&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with myeloproliferative disorders&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Manifest pulmonary hypertension&#xD;
&#xD;
          -  Significant pulmonary disease&#xD;
&#xD;
          -  Left-sided heart failure or diastolic compliance dysfunction&#xD;
&#xD;
          -  Hemodynamic relevant valvular disease&#xD;
&#xD;
          -  Systemic arterial hypertension (at rest systolic &gt;150 mmHg, diastolic &gt; 90 mmHg,&#xD;
             during exercise &gt; 220 mmHg)&#xD;
&#xD;
          -  Severe anemia&#xD;
&#xD;
          -  Uncontrolled supraventricular and ventricular arrhythmias&#xD;
&#xD;
          -  Myocardial infarction (within the last 12 months)&#xD;
&#xD;
          -  Pulmonary embolism (within the last 12 months)&#xD;
&#xD;
          -  Recent therapy changes (within the last 12 months)&#xD;
&#xD;
          -  Recent major surgeries (within the last 12 months)&#xD;
&#xD;
          -  For exercise tests: musculoskeletal diseases which may unable the exercise tests&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Horst Olschewski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz, Pulmonology</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>October 10, 2012</study_first_submitted>
  <study_first_submitted_qc>February 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2013</study_first_posted>
  <last_update_submitted>September 7, 2015</last_update_submitted>
  <last_update_submitted_qc>September 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloproliferative disorders</keyword>
  <keyword>pulmonary hypertension</keyword>
  <keyword>pulmonary vascular diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

